Iridex Expands Its EyeProGPO Product Offering To Include The Company’s Line Of EndoProbe Handpieces
IRIDEX Corp IRIX
$0.82
▼ -1.39%
($-0.01)
📉 Near 52W Low
🗓️ Earnings Next Week
Open
$0.84
Prev Close
$0.83
Day Range
$0.82 – $0.88
52W Range
$0.80 – $1.65
Market Cap
$14.27M
Beta
0.63
EPS (TTM)
$-0.19
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1996-02-16 |
| Shares Out. | 17,410,000 |
| Website | iridex.com/ ↗ |
| Phone | 13026587581 |
| Employees | 108 |
| Revenue | $11.8M |
| Gross Profit | $4.7M |
| Net Income | -$524,000 |
| Free Cash Flow | -$2.5M |
| Total Assets | $28.3M |
| Total Liabilities | $23.5M |
| Equity | $4.7M |
About IRIDEX Corp
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
IRIDEX Corp is a publicly traded company under the ticker symbol IRIX on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)